{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:40:08Z","timestamp":1761100808435},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: In patients treated with allogeneic stem cell transplantation for advanced mantle cell lymphoma (MCL), complete sustained remissions have been observed illustrating susceptibility of MCL cells to a graft-versus-lymphoma effect. To potentiate this graft-versus-lymphoma effect, adoptive transfer of in vitro selected MCL-specific CTL can be an attractive approach. The lack of expression of costimulatory molecules on MCL cells hampers the generation of MCL-reactive T-cell responses. The purpose of this study was to modify MCL cells into antigen-presenting cells (APC) and to use these MCL-APCs to induce allogeneic MCL-reactive T-cell responses.<\/jats:p>\n               <jats:p>Experimental Design: Interleukin (IL)-4, IL-10, CpG, and CD40 activation were tested for their capacity to up-regulate costimulatory molecules on MCL cells. Primary MCL cells or the modified MCL-APCs were then used to evaluate the induction of MCL-reactive T-cell responses in HLA-matched donors.<\/jats:p>\n               <jats:p>Results: Ligation of CD40 on MCL cells was essential to up-regulate costimulatory molecules and to induce production of high amounts of IL-12. In contrast to primary MCL cells, MCL-APC cells as stimulators were capable of inducing CD8+ CTL lines from HLA class I\u2013matched donors. High numbers of CTL clones could be generated capable of efficiently killing the primary MCL cells and MCL-APC but not donor-specific targets.<\/jats:p>\n               <jats:p>Conclusion: These results show the feasibility to generate primary allogeneic T-cell responses against MCL-APC, and may provide new immunotherapeutic tools to further exploit the graft-versus-lymphoma effect following allogeneic stem cell transplantation in patients with MCL.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-04-2425","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T23:49:33Z","timestamp":1127346573000},"page":"5310-5318","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Primary Allogeneic T-Cell Responses against Mantle Cell Lymphoma Antigen-Presenting Cells for Adoptive Immunotherapy after Stem Cell Transplantation"],"prefix":"10.1158","volume":"11","author":[{"given":"Mels","family":"Hoogendoorn","sequence":"first","affiliation":[{"name":"1Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, the Netherlands and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Olde Wolbers","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem M.","family":"Smit","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Ronald","family":"Schaafsma","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Jedema","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, the Netherlands and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee M.Y.","family":"Barge","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, the Netherlands and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roel","family":"Willemze","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, the Netherlands and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, the Netherlands and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"key":"2022061109362900600_B1","doi-asserted-by":"crossref","unstructured":"Li JY, Gaillard F, Moreau A, et al. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol\u20081999;154:1449\u201352.","DOI":"10.1016\/S0002-9440(10)65399-0"},{"key":"2022061109362900600_B2","doi-asserted-by":"crossref","unstructured":"Velders GA, Kluin-Nelemans JC, de Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol\u20081996;14:1269\u201374.","DOI":"10.1200\/JCO.1996.14.4.1269"},{"key":"2022061109362900600_B3","doi-asserted-by":"crossref","unstructured":"Vandenberghe E, Ruiz dE, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol\u20082003;120:793\u2013800.","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"2022061109362900600_B4","doi-asserted-by":"crossref","unstructured":"Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol\u20082004;22:1460\u20138.","DOI":"10.1200\/JCO.2004.10.054"},{"key":"2022061109362900600_B5","doi-asserted-by":"crossref","unstructured":"Jacobsen E, Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol\u20082004;16:106\u201313.","DOI":"10.1097\/00001622-200403000-00004"},{"key":"2022061109362900600_B6","doi-asserted-by":"crossref","unstructured":"Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol\u20082004;15:504\u201310.","DOI":"10.1093\/annonc\/mdh090"},{"key":"2022061109362900600_B7","doi-asserted-by":"crossref","unstructured":"Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol\u20082004;15:283\u201390.","DOI":"10.1093\/annonc\/mdh069"},{"key":"2022061109362900600_B8","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Romaguera J, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol\u20081999;10:1293\u20139.","DOI":"10.1023\/A:1008380527502"},{"key":"2022061109362900600_B9","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol\u20081998;16:2817\u201324.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2022061109362900600_B10","doi-asserted-by":"crossref","unstructured":"Barge RM, Osanto S, Marijt WA, et al. Minimal GVHD following in vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol\u20082003;31:865\u201372.","DOI":"10.1016\/S0301-472X(03)00200-5"},{"key":"2022061109362900600_B11","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood\u20082001;98:3595\u20139.","DOI":"10.1182\/blood.V98.13.3595"},{"key":"2022061109362900600_B12","doi-asserted-by":"crossref","unstructured":"Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood\u20082004;104:1550\u20138.","DOI":"10.1182\/blood-2004-03-0804"},{"key":"2022061109362900600_B13","doi-asserted-by":"crossref","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood\u20082002;100:4310\u20136.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2022061109362900600_B14","doi-asserted-by":"crossref","unstructured":"Falkenburg JH, van de Corp, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol\u20082003;31:743\u201351.","DOI":"10.1016\/S0301-472X(03)00190-5"},{"key":"2022061109362900600_B15","doi-asserted-by":"crossref","unstructured":"Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood\u20081999;93:1992\u20132002.","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002"},{"key":"2022061109362900600_B16","doi-asserted-by":"crossref","unstructured":"Ranheim EA, Kipps TJ. Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med\u20081993;177:925\u201335.","DOI":"10.1084\/jem.177.4.925"},{"key":"2022061109362900600_B17","doi-asserted-by":"crossref","unstructured":"Hoogendoorn M, Wolbers JO, Smit WM, et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia\u20082004;18:1278\u201387.","DOI":"10.1038\/sj.leu.2403358"},{"key":"2022061109362900600_B18","doi-asserted-by":"crossref","unstructured":"Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol\u20081994;12:881\u2013922.","DOI":"10.1146\/annurev.iy.12.040194.004313"},{"key":"2022061109362900600_B19","doi-asserted-by":"crossref","unstructured":"Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood\u20082002;99:3319\u201325.","DOI":"10.1182\/blood.V99.9.3319"},{"key":"2022061109362900600_B20","doi-asserted-by":"crossref","unstructured":"Schultze JL, Cardoso AA, Freeman GJ, et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A\u20081995;92:8200\u20134.","DOI":"10.1073\/pnas.92.18.8200"},{"key":"2022061109362900600_B21","doi-asserted-by":"crossref","unstructured":"Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood\u20081996;88:41\u20138.","DOI":"10.1182\/blood.V88.1.41.bloodjournal88141"},{"key":"2022061109362900600_B22","doi-asserted-by":"crossref","unstructured":"Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood\u20082000;95:999\u20131006.","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006"},{"key":"2022061109362900600_B23","doi-asserted-by":"crossref","unstructured":"Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature\u20081995;374:546\u20139.","DOI":"10.1038\/374546a0"},{"key":"2022061109362900600_B24","doi-asserted-by":"crossref","unstructured":"Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood\u20082003;102:956\u201363.","DOI":"10.1182\/blood-2002-11-3355"},{"key":"2022061109362900600_B25","doi-asserted-by":"crossref","unstructured":"Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood\u20082003;101:4500\u20134.","DOI":"10.1182\/blood-2002-11-3569"},{"key":"2022061109362900600_B26","doi-asserted-by":"crossref","unstructured":"Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol\u20082000;164:944\u201353.","DOI":"10.4049\/jimmunol.164.2.944"},{"key":"2022061109362900600_B27","doi-asserted-by":"crossref","unstructured":"Krackhardt AM, Harig S, Witzens M, et al. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood\u20082002;100:167\u201373.","DOI":"10.1182\/blood.V100.1.167"},{"key":"2022061109362900600_B28","doi-asserted-by":"crossref","unstructured":"Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest\u20081998;101:1133\u201341.","DOI":"10.1172\/JCI1472"},{"key":"2022061109362900600_B29","doi-asserted-by":"crossref","unstructured":"van de Corp, Kluin-Nelemans HC, Kester MG, Willemze R, Falkenburg JH. Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones. Blood\u20081999;93:251\u20139.","DOI":"10.1182\/blood.V93.1.251"},{"key":"2022061109362900600_B30","doi-asserted-by":"crossref","unstructured":"Mongini PK, Tolani S, Fattah RJ, Inman JK. Antigen receptor triggered up-regulation of CD86 and CD80 in human B cells: augmenting role of the CD21\/CD19 co-stimulatory complex and IL-4. Cell Immunol\u20082002;216:50\u201364.","DOI":"10.1016\/S0008-8749(02)00512-9"},{"key":"2022061109362900600_B31","doi-asserted-by":"crossref","unstructured":"Visser HP, Tewis M, Willemze R, Kluin-Nelemans JC. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia\u20082000;14:1483\u20139.","DOI":"10.1038\/sj.leu.2401829"},{"key":"2022061109362900600_B32","doi-asserted-by":"crossref","unstructured":"Vaandrager JW, Schuuring E, Zwikstra E, et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood\u20081996;88:1177\u201382.","DOI":"10.1182\/blood.V88.4.1177.bloodjournal8841177"},{"key":"2022061109362900600_B33","doi-asserted-by":"crossref","unstructured":"Banchereau J, Rousset F. Growing human B lymphocytes in the CD40 system. Nature\u20081991;353:678\u20139.","DOI":"10.1038\/353678a0"},{"key":"2022061109362900600_B34","doi-asserted-by":"crossref","unstructured":"Smit WM, Rijnbeek M, van Bergen CA, et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol\u20081997;53:216\u201323.","DOI":"10.1016\/S0198-8859(96)00285-6"},{"key":"2022061109362900600_B35","doi-asserted-by":"crossref","unstructured":"Jedema I, Van Der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood\u20082004;103:2677\u201382.","DOI":"10.1182\/blood-2003-06-2070"},{"key":"2022061109362900600_B36","doi-asserted-by":"crossref","unstructured":"Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res\u20082005;11:1490\u20139.","DOI":"10.1158\/1078-0432.CCR-04-1890"},{"key":"2022061109362900600_B37","doi-asserted-by":"crossref","unstructured":"Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev\u20081996;10:111\u201327.","DOI":"10.1016\/S0268-960X(96)90040-5"},{"key":"2022061109362900600_B38","unstructured":"Airoldi I, Guglielmino R, Ghiotto F, et al. Cytokine gene expression in neoplastic B cells from human mantle cell, follicular, and marginal zone lymphomas and in their postulated normal counterparts. Cancer Res\u20082001;61:1285\u201390."},{"key":"2022061109362900600_B39","doi-asserted-by":"crossref","unstructured":"Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood\u20081999;94:1201\u20138.","DOI":"10.1182\/blood.V94.4.1201.416k08_1201_1208"},{"key":"2022061109362900600_B40","doi-asserted-by":"crossref","unstructured":"Falkenburg JH, Smit WM, Willemze R. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev\u20081997;157:223\u201330.","DOI":"10.1111\/j.1600-065X.1997.tb00985.x"},{"key":"2022061109362900600_B41","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol\u20082003;21:4407\u201312.","DOI":"10.1200\/JCO.2003.05.501"},{"key":"2022061109362900600_B42","doi-asserted-by":"crossref","unstructured":"Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood\u20082004;104:3535\u201342.","DOI":"10.1182\/blood-2004-06-2275"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/11\/14\/5310\/1958556\/5310-5318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/11\/14\/5310\/1958556\/5310-5318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T22:49:46Z","timestamp":1654987786000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/11\/14\/5310\/290706\/Primary-Allogeneic-T-Cell-Responses-against-Mantle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,15]]},"references-count":42,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2005,7,20]]},"published-print":{"date-parts":[[2005,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-2425","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,15]]}}}